LINK: https://bswhealth.webex.com/bswhealth/j.php?MTID=m9c241009dd66e79040cc57f992abc2f1

OBJECTIVES: Upon completion of this activity, the participant should be able to:  (1) Review the pathophysiology and updated diagnostic criteria of hepatorenal syndrome – acute kidney injury (HRS-AKI). (2) Evaluate the role and efficacy of terlipressin as the only FDA-approved treatment for HRS-AKI.  (3) Discuss current management strategies, patient selection, treatment options, and risk-benefit concerns for patients with HRS-AKI. 

FACULTY DISCLOSURE: Stevan Gonzalez, MD, had consultant/ Advisory Board relationship n the speaker’s bureau for with Mallinckrodt Pharmaceuticals, Salix Pharmaceuticals, and Abbvie Pharmaceuticals.

PLANNER DISCLOSURE: James Trotter, MD, Sumeet Asrani, MD, Gregory McKenna, MD, and Kathy Brown, RN, CCTC, have no relevant financial relationship(s) to disclose with companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships have been mitigated.

ACCREDITATION: The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

DESIGNATION:  The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CEPTC Credit: The American Board for Transplant Certification (ABTC) has been applied for educational offering for up to 1 Category 1 Continuing Education Point for Transplant Certification (CEPTCs).

For information, please contact Karina Pena at [email protected]